Skip to content

Released Mar 20, 2025, after the close

10-K filed Mar 20, 2025, 79 days after period end · 0000950170-25-042673

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$7.36Mderived+2.7% vs Q4 2023+7.5% vs Q3 2024
Net Income-$10.34MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,532,000N/M
Operating Cash Flowderived-$407,000N/M
Free Cash Flowderived-$407,000N/M
Margins · derived
Operating margin-156.7%+18.5 pt vs Q4 2023
Net margin-140.5%+12.6 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$7.36M$7.16M——
Net Income-$10.34M-$10.96M-$22.40M-$60.26M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR